Patents Assigned to Errant Gene Therapeutics, LLC
-
Patent number: 9486421Abstract: Lung disease, such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), asthma or acute and chronic bronchitis, can be treated with an oxyamide-containing compound.Type: GrantFiled: December 26, 2007Date of Patent: November 8, 2016Assignee: ERRANT GENE THERAPEUTICS, LLCInventor: Hsuan-Yin Lan-Hargest
-
Patent number: 8420698Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.Type: GrantFiled: December 23, 2010Date of Patent: April 16, 2013Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L Wiech
-
Patent number: 8138225Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-ketoepoxide group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or to stimulate hematopoietic cells ex vivo.Type: GrantFiled: August 21, 2009Date of Patent: March 20, 2012Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman
-
Patent number: 8026280Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy. Carboxylic acid-containing compounds having a terminal cyclic moiety, a carboxylic acid group, and a C3-12 hydrocarbon chain optionally containing at least one double bond, at least one triple bond, or at least one double bond and one triple bond linking the cyclic moiety and the carboxylic acid group are inhibitors of histone deacetylase.Type: GrantFiled: December 26, 2001Date of Patent: September 27, 2011Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L Wiech
-
Patent number: 7902259Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.Type: GrantFiled: February 17, 2005Date of Patent: March 8, 2011Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L Wiech
-
Patent number: 7858664Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.Type: GrantFiled: December 23, 2004Date of Patent: December 28, 2010Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L Wiech
-
Patent number: 7842727Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, genetic disorders, e.g. Huntington's disease and spinal muscular atrophy and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.Type: GrantFiled: July 20, 2006Date of Patent: November 30, 2010Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L. Wiech
-
Patent number: 7579372Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-ketoepoxide group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or to stimulate hematopoietic cells ex vivo.Type: GrantFiled: August 8, 2005Date of Patent: August 25, 2009Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman
-
Patent number: 7314953Abstract: Lung disease, such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), asthma or acute and chronic bronchitis, can be treated with an oxyamide-containing compound.Type: GrantFiled: November 19, 2003Date of Patent: January 1, 2008Assignee: Errant Gene Therapeutics, LLCInventors: Norbert L. Wiech, Hsuan-Yin Lan-Hargest
-
Patent number: 7312247Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.Type: GrantFiled: March 27, 2001Date of Patent: December 25, 2007Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L Wiech
-
Patent number: 7214831Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-chalcogenmethylcarbonyl group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or for stimulating hematopoietic cells ex vivo.Type: GrantFiled: May 21, 2003Date of Patent: May 8, 2007Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman
-
Patent number: 7193105Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, a trihalomethylcarbonyl group, such as a trifluoromethylcarbonyl group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or for stimulating hematopoietic cells ex vivo.Type: GrantFiled: May 21, 2003Date of Patent: March 20, 2007Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman
-
Patent number: 7057057Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-ketoepoxide group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or to stimulate hematopoietic cells ex vivo.Type: GrantFiled: May 21, 2003Date of Patent: June 6, 2006Assignee: Errant Gene Therapeutics, LLCInventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman